Patient characteristics
| Age . | Disease . | Stage at diagnosis . | Previous lines of therapy . | Response to previous line of therapy . | Dose level . |
|---|---|---|---|---|---|
| 53 | ATLL, acute | 4 | Ruxolitinib, rhIL-15 with avelumab | PR | 1 |
| 62 | SS | 4B (T4N1M0B2) | Bexarotene, extracorporeal photopheresis, interferon alpha, vorinostat, alemtuzumab, mogamulizumab, pembrolizumab + TTI-621, doxil | CR | 1 |
| 65 | ATLL, acute | 4 | EPOCH | PD | 1 |
| 46 | ATLL, lymphomatous | 4 | CHOP, rhIL-15 with alemtuzumab | PD | 2 |
| 30 | ATLL, acute | 4 | CHOP, GDP | PD | 2 |
| 63 | MF | 2A (T2N0M0B0) | CHOP, brentuximab vedotin, bendamustine, rhIL-15 with avelumab | PD | 2 |
| Age . | Disease . | Stage at diagnosis . | Previous lines of therapy . | Response to previous line of therapy . | Dose level . |
|---|---|---|---|---|---|
| 53 | ATLL, acute | 4 | Ruxolitinib, rhIL-15 with avelumab | PR | 1 |
| 62 | SS | 4B (T4N1M0B2) | Bexarotene, extracorporeal photopheresis, interferon alpha, vorinostat, alemtuzumab, mogamulizumab, pembrolizumab + TTI-621, doxil | CR | 1 |
| 65 | ATLL, acute | 4 | EPOCH | PD | 1 |
| 46 | ATLL, lymphomatous | 4 | CHOP, rhIL-15 with alemtuzumab | PD | 2 |
| 30 | ATLL, acute | 4 | CHOP, GDP | PD | 2 |
| 63 | MF | 2A (T2N0M0B0) | CHOP, brentuximab vedotin, bendamustine, rhIL-15 with avelumab | PD | 2 |
CHOP, cyclophosphamide, doxorubicin, vincristine, prednisone; CR, complete response; EPOCH, etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin; GDP, gemcitabine, cisplatin, dexamethasone; PD, progressive disease; PR, partial response.